J&J's Nipocalimab Receives FDA Breakthrough Therapy Designation for Sjögren's Disease
CompanyDrug

J&J’s Nipocalimab Receives FDA Breakthrough Therapy Designation for Sjögren’s Disease

Zai Lab and argenx Receive NMPA Approval for Vygart Hytrulo in Chronic Inflammatory Demyelinating Polyneuropathy
CompanyDrug

Zai Lab and argenx Receive NMPA Approval for Vygart Hytrulo in Chronic Inflammatory Demyelinating Polyneuropathy

Cutia Therapeutics' CU-10201 Receives NMPA Approval for Acne Vulgaris Treatment
CompanyDrug

Cutia Therapeutics’ CU-10201 Receives NMPA Approval for Acne Vulgaris Treatment

BeyondSpring Presents Positive Phase II Data for Plinabulin Combination Therapy in NSCLC at SITC
CompanyDrug

BeyondSpring Presents Positive Phase II Data for Plinabulin Combination Therapy in NSCLC at SITC

Abbisko Therapeutics' Pimicotinib Meets Primary Endpoint in Phase III MANEUVER Study for TGCT
CompanyDrug

Abbisko Therapeutics’ Pimicotinib Meets Primary Endpoint in Phase III MANEUVER Study for TGCT

ETERN Therapeutics' ETS-006 Receives FDA Orphan Drug Designation for Pleural Mesothelioma
CompanyDrug

ETERN Therapeutics’ ETS-006 Receives FDA Orphan Drug Designation for Pleural Mesothelioma

Frontera Therapeutics Receives FDA Approval for Phase II Study of FT-003 in nAMD
CompanyDrug

Frontera Therapeutics Receives FDA Approval for Phase II Study of FT-003 in nAMD

Viatris Reports Q3 2024 Global Sales of USD 3.8 Billion with a 5% YOY Decline
Company

Viatris Reports Q3 2024 Global Sales of USD 3.8 Billion with a 5% YOY Decline

Gilead Sciences Reports 7% YOY Increase in Q3 2024 Product Sales, Driven by HIV Therapies
Company

Gilead Sciences Reports 7% YOY Increase in Q3 2024 Product Sales, Driven by HIV Therapies

GSK Leaves BIO, Joining Other Major Companies in Withdrawing Membership
Company

GSK Leaves BIO, Joining Other Major Companies in Withdrawing Membership

ATLATL and Takeda Enter MoU to Collaborate on Early-Stage Drug Development and Innovation
CompanyDeals

ATLATL and Takeda Enter MoU to Collaborate on Early-Stage Drug Development and Innovation

Alteogen Secures Exclusive Licensing Deal with Daiichi Sankyo for Subcutaneous Enhertu
CompanyDeals

Alteogen Secures Exclusive Licensing Deal with Daiichi Sankyo for Subcutaneous Enhertu